Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Alan Lukazewski"'
Autor:
Mary Pesik, Kari Trapskin, Hailey Thompson, Lena Swander, Alan Lukazewski, Tim Bartholow, Rebecca Cohen
Publikováno v:
Preventing Chronic Disease
Heart disease and stroke are leading causes of death and disability in the United States, and high blood pressure is a major risk factor for both. Community pharmacists are readily positioned to improve cardiovascular health through services such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d9d9dafe726b86a9158d62e523a586
https://doi.org/10.5888/pcd17.200058
https://doi.org/10.5888/pcd17.200058
Publikováno v:
The Consultant Pharmacist. 29:689-697
Primary, to evaluate the usefulness of a comprehensive medication review (CMR) process in screening for adverse drug event (ADE) risk and to measure the impact of pharmacist recommendations; secondary, to evaluate whether screening tools assist in de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::793fe857d8d82f20da6b3babfe8b8f71
https://doi.org/10.4140/tcp.n.2014.689.
https://doi.org/10.4140/tcp.n.2014.689.
Publikováno v:
The Consultant Pharmacist. 27:106-113
OBJECTIVE: The primary objective was to evaluate the effectiveness of a Web-based program, Monitor-Rx, in identifying older adults at risk for drug-related geriatric syndromes or inappropriate medicines. DESIGN: This prospective pilot study compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79d44914d7c6060eea9db8f5eaf5702
https://doi.org/10.4140/tcp.n.2012.106
https://doi.org/10.4140/tcp.n.2012.106
Autor:
Janet Kohli, Alan Lukazewski
Publikováno v:
The Consultant Pharmacist. 26:449-450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::871ee35dee55098fc5be25e62d95d156
https://doi.org/10.4140/tcp.n.2011.449
https://doi.org/10.4140/tcp.n.2011.449
Publikováno v:
Critical Care Medicine. 14:886-888
Ten patients with symptomatic atrial tachyarrhythmias were treated with an iv verapamil bolus (mean 8.5 mg) followed by a continuous verapamil infusion (mean dose 9.4 mg/h). The infusions were titrated to ventricular rate and continued for an average
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9561eb4727f021166e82679aa0b64b24
https://doi.org/10.1097/00003246-198610000-00011
https://doi.org/10.1097/00003246-198610000-00011